MED.SWMED.SWSIX
Loading
| Metric | Q2 2023 | Q4 2023 | Q2 2024 | Q4 2024 | Q2 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +40.34% | +26.01% | +26.19% | +19.97% | +19.17% |
| Gross Profit Growth | +29.70% | +20.93% | +21.13% | +17.96% | +22.70% |
| EBITDA Growth | -20.77% | +64.19% | +44.45% | +167.13% | +50.95% |
| Operating Income Growth | -53.96% | +74.86% | -423.13% | +0.00% | +232.16% |
| Net Income Growth | -111.97% | +0.00% | +67901.06% | +0.00% | +0.00% |
| EPS Growth | -111.67% | +0.00% | +63233.33% | +0.00% | +0.00% |
| EPS Diluted Growth | -111.67% | +0.00% | +63233.33% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.63% | +4.61% | +14.08% | +4.74% | -0.26% |
| Weighted Average Shares Diluted Growth | +2.63% | +4.61% | +14.08% | +4.74% | +2.65% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -132.38% | +90.43% | +0.00% | +3113.53% | +0.00% |
| Free Cash Flow Growth | -455.19% | +81.02% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +66.53% | +27.42% | +0.00% | +2.78% | -15.36% |
| Inventory Growth | +32.42% | +25.78% | +16.68% | +13.22% | +18.94% |
| Asset Growth | +20.73% | +17.22% | +39.18% | +40.28% | +31.24% |
| Book Value per Share Growth | +16.68% | +8.81% | -1.71% | +8.27% | -1.16% |
| Debt Growth | +68.54% | +75.15% | +148.40% | +132.96% | +190.44% |
| R&D Expense Growth | +27.64% | +30.98% | +82.60% | +58.73% | +1.25% |
| SG&A Expenses Growth | +41.50% | +14.70% | +18.51% | +5.01% | +19.52% |